Zurich Cantonal Bank
SPRY icon

Zurich Cantonal Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Zurich Cantonal Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,662
Closed -$136K – 3385
2025
Q4 		$136K Buy
+11,662
New +$113K ﹤0.01% 2338

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Zurich Cantonal Bank's SPRY Position: Q2 2026 in Review

Zurich Cantonal Bank increased its ARS Pharmaceuticals (SPRY) stake by 111% in Q2 2026, buying an estimated $112K and bringing the position to 24,649 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #2308.

Zurich Cantonal Bank first reported a position in SPRY in Q1 2023 and has held it in 13 quarters since. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Zurich Cantonal Bank held 24,649 shares of ARS Pharmaceuticals worth $197K as of Q2 2026.
  • Zurich Cantonal Bank bought 12,987 ARS Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • ARS Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2308 holding.
  • Zurich Cantonal Bank first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.